Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Optimizing Therapy with Radium-223 for Prostate Cancer

October 12th 2017

Prostate Cancer: Combination Therapy with Radium-223

October 12th 2017

Bone-Targeted Therapy for Prostate Cancer: Radium-223

October 12th 2017

mCRPC Therapy: Considerations in Therapy Selection

October 12th 2017

The Value of Therapeutic Layering in mCRPC

October 12th 2017

Hormone-Sensitive Prostate Cancer: Nuances in Therapy

October 12th 2017

Hormone-Sensitive PC: What is the Standard of Care?

October 12th 2017

Considering the Role of ADT in Advanced Prostate Cancer

October 12th 2017

Monitoring Advanced Prostate Cancer: Next-Gen Imaging

October 12th 2017

Metastatic Prostate Cancer: Testing for BRCA Mutations

October 12th 2017

The Impact of DNA Repair Defects on Prostate Cancer

October 12th 2017

Metastatic Prostate Cancer: Intrinsic Genomic Subtypes

October 12th 2017

Metastatic Prostate Cancer: Androgen Receptor Biology

October 12th 2017

The Underlying Biology of Metastatic Prostate Cancer

October 12th 2017

Dr. Loeb on the Impact of Additional Testing for Prostate Cancer

October 11th 2017

Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses the impact of different genomic tests for patients with prostate cancer.

FDA Approval Sought for Apalutamide in Prostate Cancer

October 11th 2017

A new drug application has been submitted to the FDA for apalutamide (ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC).

Dr. Feldman on Men With Prostate Cancer Receiving Treatment After Active Surveillance

October 10th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of surgery, Harvard Medical School, discusses men with prostate cancer receiving treatment after active surveillance.

Precision Medicine Has Emerging Role in mCRPC

October 6th 2017

Andrew J. Armstrong, MD, discusses emerging treatments and techniques for precision medicine in metastatic castration-resistant prostate cancer.

Novel Imaging Techniques Advancing Prostate Cancer Care

October 5th 2017

William R. Berry, MD, discusses luteinizing hormone-releasing hormone agonists versus antagonists as treatment options for patients and highlights the novel techniques for prostate cancer imaging.

Phase III Data Show Benefit With Abiraterone in Castration-Sensitive Prostate Cancer

October 4th 2017

Tian Zhang, MD, discusses emerging results for patients with metastatic castration-sensitive prostate cancer.